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Systemic vasculitides are poorly understood inﬂammatory diseases of the blood vessels that are
frequently associated with signiﬁcant organ damage. Genetic risk variants contribute to the susceptibility
of vasculitis, but functional consequences of these genetic variants are largely unknown. Most genetic
risk variants in immune-mediated diseases, including systemic vasculitis, are localized to non-coding
genetic regions suggesting they might increase disease risk by inﬂuencing regulatory elements within
the genome. Long range regulatory interactions pose an additional obstacle in localizing functional
consequences associated with risk variants to speciﬁc genes or cell types. We used cell-type speciﬁc
enrichment patterns of histone changes that mark poised, primed, and active enhancers, and DNase
hypersensitivity to identify speciﬁc immune cells mediating genetic risk in vasculitis. Our data suggest
that genetic risk variants in ANCA-associated vasculitis are signiﬁcantly enriched in enhancer elements in
Th17 cells, supporting a role for Th17 cells in this disease. Primed and active enhancer elements in B cells
can be potentially affected by genetic risk variants associated with Kawasaki disease. Genetic risk in
Behçet's disease and Takayasu arteritis might affect enhancer elements in multiple cell types, possibly
explained by inﬂuencing enhancers in hematopoietic stem cells. Interestingly, our analyses indicate a
role for B cells in Kawasaki disease, Behçet's disease, and Takayasu arteritis, and suggest that further
work to characterize the involvement of B cells in these diseases is warranted.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic vasculitides are a group of rare inﬂammatory diseases
of the blood vessels that can lead to signiﬁcant morbidity and
mortality. As a group, they can affect any blood vessel in the arterial
or venous system, leading to stenosis, tissue ischemia, and blood
clot formation. Most vasculitides fall into one of 4 categories; large
vessel, medium vessel, small vessel, and variable vessel disease,
reﬂecting predilection to involve speciﬁc parts of the vascular tree
[1]. These diseases are commonly associated with systemic mani-
festations, and can result in organ dysfunction and damage.
The etiology of systemic vasculitis is unknown, and the patho-
genesis remains poorly understood. A role for genetic susceptibility
in systemic vasculitis is supported by familial aggregation,150 W. Medical Center Drive,
a).
Ltd. This is an open access article uvariations in prevalence based on ethnicity, and a number of ge-
netic susceptibility variants that are more frequently present in
patients with systemic vasculitis compared to normal healthy
controls. Indeed, recent genome-wide association studies (GWAS)
have uncovered a number of genetic susceptibility variants in
ANCA-associated vasculitis (AAV) [2], Kawasaki disease [3], Behçet's
disease [4], and Takayasu arteritis [5e7]. More recent data suggest
the involvement of epigenetic variants, particularly DNA methyl-
ation changes, in the pathogenesis of vasculitis [8]. In some
vasculitides, such as Behçet's disease, speciﬁc and reversible
epigenetic changes that underlie the disease pathogenesis can
differentiate between active and inactive disease [9].
Despite recent progress, an understanding of basic initiating
pathogenic mechanisms in most vasculitides is lacking. In fact,
functional characterization of genetic variants known to underlie
the susceptibility to vasculitis remains a bottle neck hindering any
progress towards understanding the pathogenesis of vasculitis, and
indeed, in most forms of immune-mediated diseases. Systemic
vasculitides are inﬂammatory diseases, and therefore a prominentnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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critical in disease initiation and progression. However, it remains
unknownwhat speciﬁc cell types are most critically involved in the
various forms of vasculitis. Until this is understood, targeted ther-
apy will be difﬁcult to achieve effectively.
Recent years have seen rapid growth of genomic organization
and functional annotation data. The Encyclopedia of DNA Elements
(ENCODE) [10] and the NIH Roadmap Epigenomics [11] projects
have aimed to identify the functional elements in the human
genome of the major cell types and tissues. Utilizing histone
modiﬁcations marking regulatory enhancer elements in 25 normal
blood cell types, we aimed to identify potential speciﬁc immune
cell types involved in the pathogenesis of various forms of vasculitis
by characterizing epigenomic marks of chromatin accessibility
enriched in genomic regions that contain genetic susceptibility
variants identiﬁed from GWAS studies in vasculitis.2. Methods
2.1. Data sources
Genetic susceptibility loci identiﬁed using a GWAS approach in
systemic vasculitis and with an association P value of  5  105
were evaluated (Table 1). Four vasculitides with published GWAS
data were included in our study. These were ANCA-associated
vasculitis (AAV), Behçet's disease, Kawasaki disease, and Takayasu
arteritis. Genomic coordinates in GRCh37/hg19 coordinate system
of vasculitis-associated loci were obtained from the dbSNP v142
database of genomic variants.
The epigenomic regulatory marks evaluated in this study
included histone 3 lysine 27 tri-methylation (H3K27me3), histone 3
lysine 4 mono-methylation (H3K4me1), histone 3 lysine 27Table 1
Genetic susceptibility loci identiﬁed using a GWAS approach in systemic vasculitis (P < 5
ANCA-associated vasculitis [18,19] Behçet's disease [20e28] K
SNP Locus SNP Locus SN
rs5941160 e rs17482078 ERAP1;LOC102724748 rs
rs1705767 ARHGAP18 rs7616215 FLT1P1 e CCR1 rs
rs17057678 ARHGAP18 rs632111 FUT2 rs
rs7059886 ASS1P4 e PRKX rs1608157 GIMAP4 rs
rs1972809 C1GALT1C1 e PA2G4P1 rs116799036 HLA-B e MICA rs
rs595018 CCDC86 rs114854070 HLA-F-AS1 e HLA-A rs
rs1949829 COBL rs1518111 IL10 rs
rs3117016 COL11A2 rs1800871 IL10 rs
rs3130233 COL11A2 rs17810546 IL12A-AS1 rs
rs4862110 DCTD rs1495965 IL23R e IL12RB2 rs
rs17281398 F8 rs924080 IL23R e IL12RB2 rs
rs5904818 FMR1 e FMR1NB rs2617170 KLRC4;KLRC4-KLRK1 rs
rs9277341 HLA-DPA1 rs12525170 PSORS1C1 e HLA-C rs
rs9277554 HLA-DPB1 rs7572482 STAT4 rs
rs5000634 HLA-DQ rs7574070 STAT4 rs
rs5954596 MAGEC2 e SPANXN4 rs897200 STAT4 rs
rs6628825 MOSPD2 rs17006292 TFCP2L1 rs
rs1623523 MYL12B e RPL31P59 rs7999348 UBAC2 rs
rs6618677 PABPC5 e SERBP1P4 rs9517668 UBAC2 rs
rs185694 PRDX2P1 e LINC00426 rs
rs62132295 PRTN3
rs6638512 RPL24P9 e NLGN4X
rs11010290 RPL7P37 e PCAT5
rs11875185 RSL24D1P11 e HMGN1P30
rs26595 SEMA6A
rs7151526 SERPINA1 e SERPINA11
rs3117242 TRNAI25
rs17065868 TSC22D1
rs2755459 UBE2V1P9 e PABPC5-AS1
rs11079740 WNT9B
rs7503953 WSCD1acetylation (H3K27ac), and DNase hypersensitivity. These epige-
netic marks were selected to determine co-localization between
vasculitis-associated genetic variants and enhancer regions within
the genome [12]. The consolidated human GRCh37/hg19 genome
annotation data from the Roadmap Epigenomics project was ob-
tained through the corresponding web-portal (http://egg2.wustl.
edu/roadmap/web_portal/index.html, Supplementary Table S1).
2.2. Functional epigenomic enrichment analysis
The functional epigenomic enrichment analysis was performed
using GenomeRunner [13]. Brieﬂy, the enrichment analysis evalu-
ates whether a set of vasculitis-associated SNPs statistically
signiﬁcantly co-localizes with functional datasets. The two-tailed
Fisher's exact test was used to calculate enrichments, or de-
pletions, of such co-localization. A ‘background’, or ‘universe’ of all
common SNPs from dbSNP v142 was used to evaluate functional
enrichments that occur by chance. The enrichment P values were
corrected for multiple testing using a False Discovery Rate (FDR)
calculation.
2.3. Functional epigenomic similarity analysis
To compare whether different sets of vasculitis-associated SNPs
are enriched in similar epigenomic signatures, the functional epi-
genomic similarity analysis [14] was performed. The functional
epigenomic similarity analysis evaluates whether global patterns of
SNP set-speciﬁc functional enrichments are similar among the SNP
sets. Brieﬂy, the enrichment P values for each vasculitis-associated
SNP set were elog10-transformed, and a “e“ sign added in case of
depleted associations. To evaluate functional epigenomic similarity
among vasculitis-associated SNP sets, SNP set-speciﬁc elog10- 105).
awasaki disease [29e36] Takayasu arteritis [5e7]
P Locus SNP Locus
28493229 ADCK4;ITPKC rs2242944 21q22
1568657 BTBD1 rs2836878 21q22
4813003 CD40 e CDH22 rs2836881 21q22
2130392 CENPU rs10919543 FCGR2A e FCGR3A
2736340 FAM167A e BLK rs12524487 HLA-B e MICA
2254546 FAM167A e BLK rs113452171 HLA-DQB1 e HLA-DRB1
1801274 FCGR2A rs189754752 HLA-DQB1 e HLA-DRB1
10129255 IGH rs6871626 IL12B
17136627 KCNN2;LOC101927078 rs56167332 IL12B
17667932 MED30 rs2069837 IL6
2233152 MIA;MIA-RAB4B rs410852 LILRA3
17531088 NAALADL2 rs9615754 LOC100289420 e FAM19A5
7604693 PELI1 rs665268 MLX
4894410 PISRT1 e MRPS22 rs6560480 PCSK5
9290065 PPM1L rs11675428 PPM1G e NRBP1
1569723 RPL13P2 e CD40 rs13260543 PTK2B
7656244 TECRL rs7005183 PTK2B
2857151 TRNAI25 rs11666543 RPS9 e LILRB3
527409 VKORC1P2 e OMA1 rs7956657 SLC16A7 e LOC100289417
7199343 ZFHX3 rs1113601 ZFPM2
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enrichment proﬁles) were pair-wise correlated using Spearman
correlation measure, and the signiﬁcance of correlations was
evaluated using asymptotic P values approximated using F distri-
bution (see Hmisc::rcorr R function for details). A matrix of
Spearman correlation coefﬁcients was clustered using “Euclidean”
distance to measure dissimilarity between rows and columns, and
the “average” agglomeration method. The clustered matrix is then
visualized using “Blue-Yellow-Red” color gradient, with darker
blue/red gradient indicating under/overrepresented enrichments,
respectively. All post-enrichment analyses were conducted in R/
Bioconductor environment v 3.2.0 [15,16]. The Venny v2.0.2 tool
[17] was used to create the Venn diagram.Fig. 2. Functional epigenomic similarity among vasculitis-associated SNP sets. We
computed the Spearman correlation coefﬁcient between vasculitis-speciﬁc epigenomic
enrichment proﬁles (Methods). The darker blue/red gradient represents weaker/
stronger epigenomic similarity, respectively. Each cell shows the numerical value of
the corresponding Spearman correlation coefﬁcient. The highest correlation was be-
tween Behçet's disease and Takayasu arteritis (P ¼ 1.77  1012).3. Results
We studied 31, 19, 20, and 20 independent genetic susceptibility
variants identiﬁed using GWAS in AAV [18,19], Behçet's disease
[20e28], Kawasaki disease [29e36], and Takayasu arteritis [5e7],
respectively (P 5 105) (Table 1). There was no overlap between
genetic variants associated with the 4 clinically distinct patterns of
vasculitis (Fig. 1).
We ﬁrst performed an analysis for global regulatory element
enrichment, using the epigenomics marks investigated in this
study, within genomic regions that contain genetic susceptibility
variants in systemic vasculitis, to identify overall regulatory dif-
ferences and similarities between the 4 types of vasculitis included
in this study. There was a moderate correlation between regulatory
element enrichment patterns in Behçet's disease, Takayasu arteritis,
and Kawasaki disease. However, regulatory element signature
seems to be distinct in AAV compared to the other 3 vasculitides
(Fig. 2). The highest correlation in regulatory signatures was be-
tween Behçet's disease and Takayasu arteritis (correlation
coefﬁcient ¼ 0.55, P ¼ 1.77  1012). The correlation between Ka-
wasaki disease and Behçet's disease, and between Kawasaki disease
and Takayasu arteritis were also signiﬁcant (correlation
coefﬁcient ¼ 0.19, P ¼ 0.021 for both).
To determine the relative involvement of speciﬁc types of
immune competent cells in the pathogenesis of AAV, Behçet'sFig. 1. Venn diagram showing lack of overlap among vasculitis-associated SNP sets.
The numbers in each oval represent counts of SNPs associated with a corresponding
disease. The number in each intersection shows the number of SNPs common for
overlapping ovals and corresponding diseases.disease, Kawasaki disease, and Takayasu arteritis, we compared
cell-type speciﬁc chromatin signature patterns within genetic
susceptibility regions in each of these vasculitides. H3K27me3,
H3K4me1, and H3K27ac patterns were used to determine
enrichment of systemic vasculitis-associated genetic variants in
poised (or closed), primed, and active enhancer regions, respec-
tively [12] (Table 2).
Disease susceptibility genetic variants in AAV were signiﬁ-
cantly enriched in genomic regions marked by H3K27me3 in Th17
cells, suggesting a possible functional effect of genetic risk vari-
ants in AAV on Th17 cells and therefore a role for Th17 cells in
AAV. Cell-type speciﬁc enhancer histone marks in Behçet's dis-
ease were most signiﬁcantly enriched in T cells and T cell subsets
including Th17 cells and Tregs, but also in NK cells, neutrophils,
monocytes, and B cells. Indeed, genetic susceptibility variants in
Behçet's disease co-localize with primed enhancer regions
(marked by H3K4me1) in hematopoietic stem cells, suggesting an
explanation for potential functional effect on multiple cell types
as a result of genetic risk in this disease. In Takayasu arteritis,
most signiﬁcant enrichment of enhancer marks suggests
involvement of NK cells, neutrophils, monocytes, and B cells in
this disease. Similar to Behçet's disease, genetic risk variants in
Takayasu arteritis were also located in primed enhancer regions
in hematopoietic stem cells. In Kawasaki disease, genetic risk
points to the involvement of B cells in the disease pathogenesis,
as B cell-speciﬁc primed/active enhancer regions are potentially
affected.
DNase hypersensitivity indicates chromatin accessibility, and
therefore, independently marks active enhancer regions (marked
by H3K27ac), but not poised or primed enhancers (marked by
H3K27me3 and H3K4me1, respectively). We used DNase hyper-
sensitivity data to conﬁrm cell-type speciﬁc H3K27ac patterns and
found that DNase hypersensitivity patterns independently
conﬁrmed enrichment of genetic susceptibility loci in cell-type
speciﬁc active enhancer regions and matched the data obtained
using H3K27ac enrichment (Table 3).
Table 2
Association between genomic regions containing susceptibility loci in systemic vasculitis and histone marks that identify poised (closed), primed, and active enhancer regions
in immune cells. Depicted P values have been adjusted for multiple testing.
Vasculitis Histone change Cell type P value
ANCA-associated vasculitis H3K27me3 Primary T helper 17 cells PMA-I stimulated 5.62E-04
Behçet's disease H3K27ac Primary T cells from peripheral blood 4.07E-09
H3K27ac Primary T helper cells PMA-I stimulated 3.17E-06
H3K27ac Primary T regulatory cells from peripheral blood 1.22E-05
H3K27ac Primary T helper 17 cells PMA-I stimulated 1.89E-05
H3K27ac Primary natural killer cells from peripheral blood 6.21E-05
H3K27ac Primary B cells from peripheral blood 2.78E-03
H3K27ac Primary monocytes from peripheral blood 1.26E-02
H3K4me1 Primary T helper cells from peripheral blood 4.75E-05
H3K4me1 Primary B cells from peripheral blood 2.25E-02
H3K4me1 Primary B cells from cord blood 4.37E-03
H3K4me1 Primary natural killer cells from peripheral blood 3.28E-04
H3K4me1 Primary neutrophils from peripheral blood 1.14E-03
H3K4me1 Primary hematopoietic stem cells short term culture 4.05E-03
H3K4me1 Primary hematopoietic stem cells 4.33E-03
H3K4me1 Primary hematopoietic stem cells G-CSF-mobilized Female 1.70E-02
Kawasaki disease H3K27ac Primary B cells from peripheral blood 1.06E-02
H3K4me1 Primary B cells from peripheral blood 1.29E-02
Takayasu arteritis H3K27ac Primary B cells from peripheral blood 2.37E-02
H3K27ac Primary monocytes from peripheral blood 6.56E-04
H3K4me1 Primary B cells from peripheral blood 4.06E-04
H3K4me1 Primary B cells from cord blood 1.03E-02
H3K4me1 Primary natural killer cells from peripheral blood 2.96E-05
H3K4me1 Primary neutrophils from peripheral blood 3.83E-04
H3K4me1 Primary hematopoietic stem cells short term culture 5.19E-04
H3K4me1 Primary hematopoietic stem cells 1.22E-03
H3K4me1 Primary hematopoietic stem cells G-CSF-mobilized Female 1.34E-03
H3K4me1 Primary hematopoietic stem cells G-CSF-mobilized Male 1.43E-03
Table 3
DNase hypersensitivity enrichment analysis for genetic susceptibility loci associated with systemic vasculitis. Depicted P values have been corrected for multiple testing.
Cell type DNase hypersensitivity enrichment (P value)
ANCA-associated vasculitis Behçet's disease Kawasaki disease Takayasu arteritis
Primary hematopoietic stem cells G-CSF-mobilized (Female) NS 5.58E-03 NS NS
Primary T cells from peripheral blood NS 8.23E-03 NS 1.34E-02
Primary B cells from peripheral blood NS 6.82E-05 1.92E-02 1.93E-03
Primary hematopoietic stem cells G-CSF-mobilized (Male) NS 4.51E-02 NS NS
Primary monocytes from peripheral blood NS 1.82E-05 NS 7.87E-03
Primary natural killer cells from peripheral blood NS 3.51E-04 NS 8.02E-03
Primary T cells from cord blood NS 2.13E-05 NS NS
NS, not signiﬁcant.
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Enhancers are regulatory elements predominantly located in
non-coding regions within the genome and play an important role
in regulating gene expression, sometimes thousands of base pairs
away. Primed and active enhancers are cell-type speciﬁc, and can
be identiﬁed by the presence of H3K4me1 and H3K27ac, respec-
tively. In contrast to active enhancers, primed enhancers are not
active but primed for activation in the presence of an appropriate
stimulus or activation signal. Poised or closed enhancers can be
identiﬁed by the presence of the repressive H3K27me3 histone
mark, but can also become active upon cell activation or differen-
tiation [12]. Using the distribution of histone modiﬁcations across
primary cell types, we determined enrichment of genetic variants
associated with systemic vasculitis in enhancer regions. This
allowed us to infer speciﬁc immune cells that might be involved in
the pathogenesis of systemic vasculitis by the possible disruption of
cell type-speciﬁc enhancer elements by disease-associated genetic
variants.
Most genetic susceptibility loci in complex diseases are localizedto non-coding and potentially regulatory genetic regions. For
example, the most robust genetic association in Behçet's disease
was localized to a non-coding potentially regulatory genetic variant
between HLA-B andMICA genes [28,37]. Indeed, this intergenic risk
variant likely explains the genetic risk previously attributed to HLA-
B*51 in Behçet's disease [28,38]. Physical locations of risk variants
relative to known genes may or may not be important, as long
range interactions and distant regulatory elements arewide-spread
within the genome.
Our data suggest that genetic risk variants in AAV can poten-
tially disrupt normally closed or poised enhancer regions that are
speciﬁc to Th17 cells. This supports recent reports suggesting a
cytokine proﬁle consistent with increased Th17 activity in AAV
[39,40]. Indeed, rituximab which is an anti-CD20 monoclonal
antibody commonly used to treat AAV might suppress Th17 ac-
tivity [41], suggesting that therapeutic beneﬁts from rituximab in
AAV could be in part due to its effect on Th17 responses [42]. The
effect of genetic risk in Behçet's disease and Takayasu arteritis on
primed and active enhancer regulatory elements seems to bemore
wide spread and suggests the involvement of multiple cell types in
A.H. Sawalha, M.G. Dozmorov / Journal of Autoimmunity 67 (2016) 76e8180the pathogenesis of these two diseases. Our data also indicate that
this could be at least in part explained by enrichment of genetic
susceptibility loci for Behçet's disease and Takayasu arteritis in
primed enhancer regions in hematopoietic stem cells. Interest-
ingly, genetic risk variants in Kawasaki disease, Behçet's disease,
and Takayasu arteritis are uniﬁed by potentially affecting active
enhancer regions in B cells, conﬁrmed using DNase hypersensi-
tivity patterns. While a role for B cells in the pathogenesis of Ka-
wasaki disease has been previously suspected [43], our data bring
attention to the unexpected possibility of a role for B cells and
possibly B cell targeted therapies in Behçet's disease and Takayasu
arteritis.
5. Conclusion
Weused cell-type speciﬁc histonemarks for enhancer regions to
infer potential speciﬁc immune cells that could be affected by ge-
netic risk variants in systemic vasculitis, and therefore potentially
involved in the pathogenesis of these disorders. While genetic risk
in AAV and Kawasaki disease seem to point to speciﬁc cell subsets
(Th17 cells and B cells, respectively), several cell subsets and he-
matopoietic stem cells seem to be involved and potentially explain
the genetic risk underlying Behçet's disease and Takayasu arteritis.
The suggested role for B cells in Behçet's disease and Takayasu
arteritis warrants further investigation.
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Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jaut.2015.10.002.
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